Ginkgo Bioworks secured another manufacturing deal with Merck, this time centered around improving biologic manufacturing.
According to a release on Monday, Ginkgo said that it plans to help Merck’s production become more efficient and increase output. Ginkgo may be able to net a total of $490 million in research fees, milestone payments, hitting commercial targets and receiving option license payments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.